Table 2.
Neurological outcomes
|
Primary Tx |
Patients total (n) |
1st presentation n (%) |
Neurological progressive disease n (%) |
Further Neuro tx n (%) |
Neuro death n (%) |
Median overall survival (months) |
||
|---|---|---|---|---|---|---|---|---|
| Local | New mets | Both | ||||||
|
Surgery alone |
59 |
18 (30.5) |
12 (20.3) |
4 (6.8) |
11 (18.6) |
29 (49.2) |
18 (30.5) |
12 (1–79) |
|
Surgery+ WBRT |
10 |
6 (60) |
4 (40) |
1 (10) |
1 (10) |
4 (40) |
2 (20) |
16 (8–46) |
|
RS |
16 |
1 (6.3) |
2 (12.5) |
3 (18.8) |
1 (6.3) |
6 (37.5) |
5 (31.3) |
13 (2–62) |
|
WBRT * |
23 |
3 (13.0) |
7 (30.4) |
5 (21.7) |
3 (13.0) |
10 (43.5) |
9 (39.1) |
23 (3–46) |
| Any | 114 | 29 (25.4) | 29 (25.4) | 13 (11.4) | 17 (14.9) | 50 (43.9) | 37 (32.5) | 16 (1–79) |
*most patients received WBRT from systemic oncologist at least 18 months prior to referral to brain metastases clinic.